Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07271043 · ClinicalTrials.gov registry record · NA

Nutrition+: Effect of a High-Protein Diabetes Formula on Body Composition in Type 2 Diabetes Patients Treated With Incretin Mimetics

A NA study of Type 2 Diabetes, sponsored by Joslin Diabetes Center.

Recruiting
Registry status
NA
Development phase
60
Enrollment target
1
Study location

NCT07271043 is a NA study of Type 2 Diabetes that is actively recruiting participants, run by Joslin Diabetes Center. The registered enrollment target is 60 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07271043, a NA study of Type 2 Diabetes, is actively recruiting participants, sponsored by Joslin Diabetes Center.

RECRUITING
Registry status
NA
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

A randomized clinical study to assess the efficacy of a high-protein diabetes specific formula (HPDSF) on lean muscle mass in overweight and obese patients with type 2 diabetes who are initiating treatment with incretin-mimetic drugs.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT protein supplement

Study Locations (1)

Massachusetts

  • Joslin Diabetes Center - Boston

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2026-01-01
Est. Completion 2026-12-01
Phase NA

Sponsor

Joslin Diabetes Center

73 total trials

What the Registry Record Tells You About NCT07271043

The ClinicalTrials.gov registry entry for NCT07271043 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (95% lower). The listed sponsor is Joslin Diabetes Center, which has 73 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which protein supplement is the first listed.

NCT07271043 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT07271043 about?

NCT07271043 is a clinical study titled "Nutrition+: Effect of a High-Protein Diabetes Formula on Body Composition in Type 2 Diabetes Patients Treated With Incretin Mimetics". A randomized clinical study to assess the efficacy of a high-protein diabetes specific formula (HPDSF) on lean muscle mass in overweight and obese patients with type 2 diabetes who are initiating treatment with incretin-mimetic drugs.

What is the current status of trial NCT07271043?

This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2026-01-01. Estimated completion is 2026-12-01.

What conditions does trial NCT07271043 study?

This clinical trial studies the following conditions: Type 2 Diabetes.

What interventions are being tested in trial NCT07271043?

The interventions under investigation include: protein supplement (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT07271043?

This trial is sponsored by Joslin Diabetes Center, which has 73 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07271043 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.